Dermira Inc (DERM.OQ)
* Drug results not to affect two other programs - company (Adds conference call details, analyst comment, updates share price)
March 5 Dermira Inc said on Monday it would discontinue the development of its acne drug after it failed to meet the main goals of two late-stage studies.
BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints
* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS
* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis
* Dermira and UCB agree to end collaboration agreement for Cimzia